Targeting residual risk: The rationale for the use of non-HDL cholesterol

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.

Original languageEnglish
Pages (from-to)434-437
Number of pages4
JournalSouthern Medical Journal
Volume103
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

LDL Cholesterol
Cholesterol
Apolipoproteins B
Risk Reduction Behavior
Primary Prevention
Secondary Prevention
Particle Size
Primary Health Care
Cardiovascular Diseases
lipoprotein cholesterol
Therapeutics
oxidized low density lipoprotein

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Targeting residual risk : The rationale for the use of non-HDL cholesterol. / Alla, Venkata (Mahesh); Kaushik, Manu; Mooss, Aryan N.

In: Southern Medical Journal, Vol. 103, No. 5, 05.2010, p. 434-437.

Research output: Contribution to journalReview article

@article{4402a04a82ba466db2b3f4a0d0e5e2bf,
title = "Targeting residual risk: The rationale for the use of non-HDL cholesterol",
abstract = "There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.",
author = "Alla, {Venkata (Mahesh)} and Manu Kaushik and Mooss, {Aryan N.}",
year = "2010",
month = "5",
doi = "10.1097/SMJ.0b013e3181d7e3a8",
language = "English",
volume = "103",
pages = "434--437",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Targeting residual risk

T2 - The rationale for the use of non-HDL cholesterol

AU - Alla, Venkata (Mahesh)

AU - Kaushik, Manu

AU - Mooss, Aryan N.

PY - 2010/5

Y1 - 2010/5

N2 - There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.

AB - There is a wealth of epidemiological and clinical data linking low-density lipoprotein cholesterol (LDLc) with atherosclerotic cardiovascular disease. Numerous primary and secondary prevention trials have demonstrated that reduction in LDLc leads to significant decrease in cardiovascular event rates. However, patients continue to be at significant risk for recurrent events despite aggressive LDLc lowering, reflecting a substantial residual risk. Numerous parameters like apolipoprotein B, LDL particle size, number and non-high density lipoprotein cholesterol (non-HDLc) measurement have been used to assess and address this high residual risk. Herein, we discuss the rationale and the evidence supporting the use of non-HDLc. We also discuss therapeutic options and provide a practical approach to residual risk reduction from a primary care perspective.

UR - http://www.scopus.com/inward/record.url?scp=77951795467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951795467&partnerID=8YFLogxK

U2 - 10.1097/SMJ.0b013e3181d7e3a8

DO - 10.1097/SMJ.0b013e3181d7e3a8

M3 - Review article

C2 - 20375942

AN - SCOPUS:77951795467

VL - 103

SP - 434

EP - 437

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 5

ER -